Lupin in alliance with Concord gets USFDA approval for Tacrolimus Capsules USP
12th Nov 2020

Lupin in alliance with Concord Biotech (Concord) has received approval from the United States Food and Drug Administration (USFDA) for Tacrolimus Capsules USP, 0.5 mg, 1 mg, and 5 mg, to market a generic version of Prograf Capsules, 0.5 mg, 1 mg, and 5 mg, of Astellas Pharma US, Inc.

Tacrolimus Capsules USP are indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney or heart transplants, in combination with other immunosuppressants.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.